Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Icotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ICAPE
- Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Betta Pharma
- 10 Nov 2022 Primary endpoint Disease-free survival has not been met according to results published in the Investigational New Drugs
- 10 Nov 2022 Results published in the Investigational New Drugs
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research.